MIC range, MIC50, MIC90 and modal MIC values of SMT-571 and therapeutic antimicrobials currently or previously recommended for N. gonorrhoeae isolates
| Antimicrobial, isolate group (n) . | MIC range (mg/L) . | MIC50 (mg/L) . | MIC90 (mg/L) . | Modal MIC (mg/L) . | S/I/Ra (%) . |
|---|---|---|---|---|---|
| SMT-571 | |||||
| all isolates (262) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| consecutive isolates (100) | 0.064–0.125 | 0.064 | 0.125 | 0.064 | ND |
| selected isolates (128) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| reference strains (34) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| Ceftriaxone (262) | <0.002–4 | 0.008 | 0.064 | 0.004 | 96.8/ND/3.2 |
| Cefixime (262) | <0.016–8 | <0.016 | 0.25 | <0.016 | 88.9/ND/11.1 |
| Azithromycin (262) | 0.016 to >256 | 0.5 | 2 | 1 | 44.0/13.9/42.1 |
| Spectinomycin (262) | 4 to >1024 | 16 | 16 | 16 | 98.0/ND/2.0 |
| Ciprofloxacin (262) | <0.002 to >32 | 2 | >32 | >32 | 39.7/0.0/60.3 |
| Ampicillin (262) | <0.016 to >256 | 0.5 | 4 | 1 | 27.4/59.1/13.5 |
| Tetracycline (262) | 0.125–256 | 2 | 16 | 4 | 22.2/17.5/60.3 |
| Antimicrobial, isolate group (n) . | MIC range (mg/L) . | MIC50 (mg/L) . | MIC90 (mg/L) . | Modal MIC (mg/L) . | S/I/Ra (%) . |
|---|---|---|---|---|---|
| SMT-571 | |||||
| all isolates (262) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| consecutive isolates (100) | 0.064–0.125 | 0.064 | 0.125 | 0.064 | ND |
| selected isolates (128) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| reference strains (34) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| Ceftriaxone (262) | <0.002–4 | 0.008 | 0.064 | 0.004 | 96.8/ND/3.2 |
| Cefixime (262) | <0.016–8 | <0.016 | 0.25 | <0.016 | 88.9/ND/11.1 |
| Azithromycin (262) | 0.016 to >256 | 0.5 | 2 | 1 | 44.0/13.9/42.1 |
| Spectinomycin (262) | 4 to >1024 | 16 | 16 | 16 | 98.0/ND/2.0 |
| Ciprofloxacin (262) | <0.002 to >32 | 2 | >32 | >32 | 39.7/0.0/60.3 |
| Ampicillin (262) | <0.016 to >256 | 0.5 | 4 | 1 | 27.4/59.1/13.5 |
| Tetracycline (262) | 0.125–256 | 2 | 16 | 4 | 22.2/17.5/60.3 |
ND, not determined due to lack of interpretative criteria.
MICs were determined using an agar dilution technique for SMT-571 and using the Etest method for the additional antimicrobials.
S, susceptible; I, intermediately susceptible; R, resistant. EUCAST clinical breakpoints (www.eucast.org) were applied for all antimicrobials, with the exception of SMT-571.
MIC range, MIC50, MIC90 and modal MIC values of SMT-571 and therapeutic antimicrobials currently or previously recommended for N. gonorrhoeae isolates
| Antimicrobial, isolate group (n) . | MIC range (mg/L) . | MIC50 (mg/L) . | MIC90 (mg/L) . | Modal MIC (mg/L) . | S/I/Ra (%) . |
|---|---|---|---|---|---|
| SMT-571 | |||||
| all isolates (262) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| consecutive isolates (100) | 0.064–0.125 | 0.064 | 0.125 | 0.064 | ND |
| selected isolates (128) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| reference strains (34) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| Ceftriaxone (262) | <0.002–4 | 0.008 | 0.064 | 0.004 | 96.8/ND/3.2 |
| Cefixime (262) | <0.016–8 | <0.016 | 0.25 | <0.016 | 88.9/ND/11.1 |
| Azithromycin (262) | 0.016 to >256 | 0.5 | 2 | 1 | 44.0/13.9/42.1 |
| Spectinomycin (262) | 4 to >1024 | 16 | 16 | 16 | 98.0/ND/2.0 |
| Ciprofloxacin (262) | <0.002 to >32 | 2 | >32 | >32 | 39.7/0.0/60.3 |
| Ampicillin (262) | <0.016 to >256 | 0.5 | 4 | 1 | 27.4/59.1/13.5 |
| Tetracycline (262) | 0.125–256 | 2 | 16 | 4 | 22.2/17.5/60.3 |
| Antimicrobial, isolate group (n) . | MIC range (mg/L) . | MIC50 (mg/L) . | MIC90 (mg/L) . | Modal MIC (mg/L) . | S/I/Ra (%) . |
|---|---|---|---|---|---|
| SMT-571 | |||||
| all isolates (262) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| consecutive isolates (100) | 0.064–0.125 | 0.064 | 0.125 | 0.064 | ND |
| selected isolates (128) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| reference strains (34) | 0.064–0.125 | 0.125 | 0.125 | 0.125 | ND |
| Ceftriaxone (262) | <0.002–4 | 0.008 | 0.064 | 0.004 | 96.8/ND/3.2 |
| Cefixime (262) | <0.016–8 | <0.016 | 0.25 | <0.016 | 88.9/ND/11.1 |
| Azithromycin (262) | 0.016 to >256 | 0.5 | 2 | 1 | 44.0/13.9/42.1 |
| Spectinomycin (262) | 4 to >1024 | 16 | 16 | 16 | 98.0/ND/2.0 |
| Ciprofloxacin (262) | <0.002 to >32 | 2 | >32 | >32 | 39.7/0.0/60.3 |
| Ampicillin (262) | <0.016 to >256 | 0.5 | 4 | 1 | 27.4/59.1/13.5 |
| Tetracycline (262) | 0.125–256 | 2 | 16 | 4 | 22.2/17.5/60.3 |
ND, not determined due to lack of interpretative criteria.
MICs were determined using an agar dilution technique for SMT-571 and using the Etest method for the additional antimicrobials.
S, susceptible; I, intermediately susceptible; R, resistant. EUCAST clinical breakpoints (www.eucast.org) were applied for all antimicrobials, with the exception of SMT-571.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
